our editorial on 'Current, new and emerging therapies for managing hyperglycaemia of type 2 diabetes'.¹ He has used the pages of the *BJGP* to promulgate a personal view against the tide of epidemiological and clinical trial evidence that glucose lowering has been shown to reduce microvascular events in type 2 diabetes. On the basis of the extensive evidence, consensus guidelines from national and international diabetes organisations (for example International Diabetes Foundation, American Diabetes Association, Diabetes UK, as well as NICE) have recommended the use of HbA1c as a therapeutic target — which he omitted to address. The newer trials of ADVANCE and ACCORD were trials of 'how low should one go' in terms glycaemic targets as measured by HbA1c. It is of interest that Dr Curtis fails to accept the results of the ADVANCE study where there were published treatment benefits on renal events.

The aim of our editorial was to summarise the differing drug classes available for the management of the hyperglycaemia and not to review major randomised outcome trials. There is now a wider drug choice which might allow tailoring of therapy to individuals — many of whom are overweight or poor responders to current therapies. The progressive nature of type 2 diabetes, ignored by Dr Curtis, is a key therapeutic factor resulting in a need for combination of therapies and thus a potential role for newer therapies. Due to these reasons, plus the limited glucose lowering effects of all drug classes, therapeutic agents with different modes of action to enhance glucose lowering are often required. Current clinical practice often includes considering the use of alternative drug classes that do not affect weight, since this is one of the important adverse effects of subcutaneous insulins, as well as oral insulin secretagogues and thiazolidinediones.

We owe it to our patients to be aware of therapeutic advances and place them

in the context of present therapies in order to improve glycaemia and reduce the burden of diabetes-related complications.

Neil Munro

Capelfield Surgery, Elm Road, Claygate, Esher, Surrey, KT10 0EH.
E-mail: neil.m.munro@btinternet.com

Michael Feher

Department of Clinical Pharmacology and Therapeutics, Charing Cross and Westminster Medical School, Westminster Hospital, London, SW1 2AP.

REFERENCE

1. Curtis S. Managing hyperglycaemia. *Br J Gen Pract* 2008; 58(554): 728.

DOI: 10.3399/bjgp08X342417

Undergraduate education

I was sorry to read the Back Pages article by a disappointed student who had met negativity about his choice of general practice as a career.¹ I experienced the same in 1975 from a tutor in my second year ('GP? A bright girl like you? That's a real waste'.) Fortunately, it didn't put me off, and I can reassure all students that many of us have already taken action to ensure that the undergraduate programmes across the UK and Ireland now showcase general practice to advantage. There is evidence that increasing numbers of students are choosing general practice; for example, more than 20% making a firm choice (F Lynch and A Howe, unpublished data 2008) compared to an inconstant 10%² in a study 7 years before. This reflects both high quality learning and interesting clinical experience in community-based placements.³ There is also extensive evidence that general practice is a challenging job (you won't be bored, Dan!) and has more academic opportunities than ever before, including more unanswered research questions than one life of academic endeavour could possibly cover.

It is human to talk up one's own preferences, but sadly students do still hear unfounded stereotyping and prejudice from members of one discipline about others. The RCGP, with its thriving Student Forum, its excellent new MRCGP curriculum, and its undisputed place at the table of the Academy of Royal Colleges, has led a shift of status for GP careers which is well deserved. This student has reminded us that there are still negative role models, but we can reassure him that many medical school and Deanery staff (as well as patients) now understand the value of GPs as clinicians, teachers, and researchers. Look at the work GPs do, not what is said about it — actions speak louder than words.

Amanda Howe

Professor of Primary Care, University of East Anglia, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, Norfolk, NR4 7TJ.
E-mail: amanda.howe@uea.ac.uk

REFERENCES

1. Fumledge D. GP stigma at medical school and beyond — do we need to take action? *Br J Gen Pract* 2008; 58(553): 581.
2. Howe A, Ives G. Does community-based experience alter career preference? New evidence from a prospective longitudinal cohort study of undergraduate medical students. *Med Edu* 2001; 35(4): 391–397.
3. Howe A. Patient-centred medicine through student-centred teaching — a student perspective on the key impacts of community-based learning in undergraduate medical education. *Med Edu* 2001; 35(7): 666–672.

DOI: 10.3399/bjgp08X342426

Community hospitals

As a GP trainee, I have worked in district, general, and teaching hospitals alone. However, I recently received the opportunity to do an 8-month rotation in elderly stroke care and orthopaedic rehabilitation at Woking Community Hospital.

Woking Community Hospital provides NHS Walk-in centre and emergency